Annette Whittemore

CEO, Board President & Co-Founder

Annette Whittemore is a co-founder and CEO of Nevada Center for Biomedical Research. She is also President of NVCBR’s board of directors. As President and CEO, Annette oversees the operation of the center and is responsible for creating, communicating, and implementing the center’s overall vision, mission, and goals.  Her vision, along with that of her co-founders, was to create the first bench to bedside medical research center dedicated to finding answers for those who suffer from myalgic encephalomyelitis (ME/CFS) and similar complex neuro-immune diseases.  Their combined efforts resulted in the creation of NVCBR within the Center for Molecular Medicine at the University of Nevada, Reno.

In addition to her leadership role at the center, Annette has remained a vocal advocate for disease awareness and research funding at state and national levels and has spoken at several international medical research conferences.

The University of Nevada, Reno selected Annette as Alumna of the Year in 2008 and awarded her with an honorary Doctor of Letters in 2009.

Annette feels blessed to share her life with her husband, five adult children and their spouses, and eight grandchildren.  She loves the outdoors, hiking, boating, playing sports, and reading whenever time allows.

LinkedIn

Carli West Kinne

Vice President, General Counsel & Secretary

Carli Kinne is vice president, general counsel, and secretary.  In addition to serving on the executive team and handling all legal matters, Carli manages NVCBR’s sponsored projects, technology transfer, corporate compliance, communication, and human resources functions.

Before joining NVCBR, Carli was in-house counsel for a management company, providing legal counsel to companies involved in a variety of industries, and served as judicial clerk to Nevada Supreme Court Justice Robert Rose.  Carli received her J.D., magna cum laude, from Seattle University School of Law, and her B.A., with distinction, from University of Nevada, Reno.

Carli is passionate about health and wellness and enjoys exercising by chasing around her two children and going to the gym.

LinkedIn

Kellen Jones

Study Coordinator & Office Manager

Kellen Jones brings more than 20 years of administrative experience across diverse industries to her role as study coordinator and office manager.  Kellen is responsible for many day-to-day functions of NVCBR including AR/AP, customer service, donor relations, event planning, graphic design, website maintenance, social media, and all others areas of administrative support.  As the study coordinator, Kellen communicates with study participants and works directly with the principal investigator to ensure compliance with the protocol.

Kellen worked with NVCBR on a volunteer basis beginning in 2006 and became a valued employee in 2010.  Previous to NVCBR, Kellen worked for more than 15 years as an administrative services manager, first, for a civil engineering firm and, then, for a land management company.

Kellen attended University of Nevada, Reno and Truckee Meadows Community College. In her free time, Kellen enjoys cooking, spending time with her family, and the outdoors.

LinkedIn

Kenny De Meirleir, M.D., Ph.D.

Medical Director

Kenny De Meirleir, M.D., Ph.D., is an avid physician researcher with expertise in treating patients with ME/CFS and other chronic neuro-immunological diseases. As Medical Director, Dr. De Meirleir provides essential medical and research expertise and clinical support to NVCBR. Dr. De Meirleir has published extensively in various medical journals and co-authored a book on ME/CFS titled, Chronic Fatigue Syndrome: A Biological Approach.

Dr. De Meirleir maintains an international medical practice in addition to his medical practice in Reno. In addition to his research and medical activities, Dr. De Meirleir recently retired from Free University of Belgium where he was a professor since 1985. Dr. De Meirleir earned his medical degree from the Vrije Universiteit Brussel in 1977 and went on to complete an internal medicine residency in the Department of Internal Medicine, University Hospital of Vrije Universiteit Brussel.

EDUCATION

  • 1963 – 1969 High School Education, Koninklijk Atheneum Mechelen (Belgium)
  • 1969 – 1970 First year of pre-medical education, Memphis State University (Memphis, Tennessee, U.S.A.)
  • 1970 – 1977 Medical Education, Vrije Universiteit Brussel, Doctor in Medicine (Belgium) July 1977, Magna cum Laude
  • 1977 – 1982 Internal medicine Residency, Department of Internal Medicine, university Hospital Vrije Universiteit Brussel, under supervision of Prof. Dr. R. Six. Certification in Internal Medicine, August 1982
  • 1982 – 1984 Resident in Cardiology, Algemeen Ziekenhuis, Vrije Universiteit Brussel, under supervision of Prof. Dr. P. Block, interrupted by military service
  • 1985 Ph.D. in Physiology, July 1985

SKILLS/TRAINING

  • ECFMG Certification
  • Internal Medicine
  • Physical Education
  • Sports Medicine
  • Cardiac Rehabilitation
  • Biotechnology Techniques

PROFESSIONAL EXPERIENCE

  • 2014 – Presently: Emeritus Professor with teaching position, Vrije Universiteit Brussel, faculty of psychology
  • 2006 – Presently:  Medical director Himmunitas VZW (Brussels, Belgium)- volunteer
  • 2013 – Presently: Medical Director Nevada Center for Biomedical Research
  • 1985 – 2005 Director Cardiac Rehabilitation Unit, Academic Ziekenhuis Vrije Universiteit Brussel/ Universitair Ziekenhuis Brussel
  • 1985 – 2005 Consultant Department of Cardiology, Academic Ziekenhuis Vrije Universiteit Brussel/ Universitair Ziekenhuis Brussel

HONORS AND AWARDS

  • Solvay Prize
  • NATO Research Award

SELECTED PUBLICATIONS

  1. Decreased Numbers of CD57+CD3- Cells Identify Potential Innate Immune Differences in Patients with Autism Spectrum Disorder.
    Siniscalco D, Mijatovic T, Bosmans E, Cirillo A, Kruzliak P, Lombardi VC, DE Meirleir K, Antonucci N.
    In Vivo. 2016 03-04;30(2):83-89.
  2. Genome-wide association analysis identifies genetic variations in subjects with myalgic encephalomyelitis/chronic fatigue syndrome.
    Schlauch KA, Khaiboullina SF, De Meirleir KL, Rawat S, Petereit J, Rizvanov AA, Blatt N, Mijatovic T, Kulick D, Palotás A, Lombardi VC.
    Transl Psychiatry. 2016 Feb 9;6:e730. doi: 10.1038/tp.2015.208.
  3. Human dendritic cells transfected with a human papilloma virus-18 construct display decreased mobility and upregulated cytokine production.
    Khaiboullina SF, Morzunov SP, Hall MR, De Meirleir KL, Rizvanov AA, Lombardi VC.
    Int J Oncol. 2013 Nov;43(5):1701-9. doi: 10.3892/ijo.2013.2074. Epub 2013 Aug 21.
  4. High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients.
    Frémont M, Coomans D, Massart S, De Meirleir K.
    Anaerobe. 2013 Aug;22:50-6. doi: 10.1016/j.anaerobe.2013.06.002. Epub 2013 Jun 19.
  5. Plasmacytoid dendritic cells in the duodenum of individuals diagnosed with myalgic encephalomyelitis are uniquely immunoreactive to antibodies to human endogenous retroviral proteins.
    De Meirleir KL, Khaiboullina SF, Frémont M, Hulstaert J, Rizvanov AA, Palotás A, Lombardi VC.
    In Vivo. 2013 Mar-Apr;27(2):177-87.
  6. Role of psychological aspects in both chronic pain and in daily functioning in chronic fatigue syndrome: a prospective longitudinal study.
    Meeus M, Nijs J, Van Mol E, Truijen S, De Meirleir K.
    Clin Rheumatol. 2012 Jun;31(6):921-9. doi: 10.1007/s10067-012-1946-z. Epub 2012 Feb 16.
  7. Myalgic encephalomyelitis: International Consensus Criteria.
    Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, Staines D, Powles AC, Speight N, Vallings R, Bateman L, Baumgarten-Austrheim B, Bell DS, Carlo-Stella N, Chia J, Darragh A, Jo D, Lewis D, Light AR, Marshall-Gradisbik S, Mena I, Mikovits JA, Miwa K, Murovska M, Pall ML, Stevens S.
    J Intern Med. 2011 Oct;270(4):327-38. doi: 10.1111/j.1365-2796.2011.02428.x. Epub 2011 Aug 22. Review.
  8. The latent human herpesvirus-6A genome specifically integrates in telomeres of human chromosomes in vivo and in vitro.
    Arbuckle JH, Medveczky MM, Luka J, Hadley SH, Luegmayr A, Ablashi D, Lund TC, Tolar J, De Meirleir K, Montoya JG, Komaroff AL, Ambros PF, Medveczky PG.
    Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5563-8. doi: 10.1073/pnas.0913586107. Epub 2010 Mar 8.
  9. Increased d-lactic Acid intestinal bacteria in patients with chronic fatigue syndrome.
    Sheedy JR, Wettenhall RE, Scanlon D, Gooley PR, Lewis DP, McGregor N, Stapleton DI, Butt HL, DE Meirleir KL.
    In Vivo. 2009 Jul-Aug;23(4):621-8.
  10. Severe versus Moderate criteria for the new pediatric case definition for ME/CFS.
    Jason L, Porter N, Shelleby E, Till L, Bell DS, Lapp CW, Rowe K, De Meirleir K.
    Child Psychiatry Hum Dev. 2009 Dec;40(4):609-20. doi: 10.1007/s10578-009-0147-8. Epub 2009 Jun 10.
  11. A comparison of patients with chronic fatigue syndrome in two “ideologically” contrasting clinics.
    Van Houdenhove B, Van Hoof E, Becq K, Kempke S, Luyten P, De Meirleir K.
    J Nerv Ment Dis. 2009 May;197(5):348-53. doi: 10.1097/NMD.0b013e3181a2081f.
  12. Detection of herpesviruses and parvovirus B19 in gastric and intestinal mucosa of chronic fatigue syndrome patients.
    Frémont M, Metzger K, Rady H, Hulstaert J, De Meirleir K.
    In Vivo. 2009 Mar-Apr;23(2):209-13.
  13. Exercise performance and chronic pain in chronic fatigue syndrome: the role of pain catastrophizing.
    Nijs J, Van de Putte K, Louckx F, Truijen S, De Meirleir K.
    Pain Med. 2008 Nov;9(8):1164-72. Epub 2007 Oct 3.
  14. Lower frequency of IL-17F sequence variant (His161Arg) in chronic fatigue syndrome patients.
    Metzger K, Frémont M, Roelant C, De Meirleir K.
    Biochem Biophys Res Commun. 2008 Nov 7;376(1):231-3. doi: 10.1016/j.bbrc.2008.08.135. Epub 2008 Sep 5.
  15. Unravelling intracellular immune dysfunctions in chronic fatigue syndrome: interactions between protein kinase R activity, RNase L cleavage and elastase activity, and their clinical relevance.
    Meeus M, Nijs J, McGregor N, Meeusen R, De Schutter G, Truijen S, Frémont M, Van Hoof E, De Meirleir K.
    In Vivo. 2008 Jan-Feb;22(1):115-21.
  16. Comparison of two exercise testing protocols in patients with chronic fatigue syndrome.
    Nijs J, Zwinnen K, Meeusen R, de Geus B, De Meirleir K.
    J Rehabil Res Dev. 2007;44(4):553-9.
  17. Defining the occurrence and influence of alpha-delta sleep in chronic fatigue syndrome.
    Van Hoof E, De Becker P, Lapp C, Cluydts R, De Meirleir K.
    Am J Med Sci. 2007 Feb;333(2):78-84.
  18. Chronic musculoskeletal pain in chronic fatigue syndrome: recent developments and therapeutic implications.
    Nijs J, Meeus M, De Meirleir K.
    Man Ther. 2006 Aug;11(3):187-91. Epub 2006 Jun 14. Review.
  19. Generalized joint hypermobility is more common in chronic fatigue syndrome than in healthy control subjects.
    Nijs J, Aerts A, De Meirleir K.
    J Manipulative Physiol Ther. 2006 Jan;29(1):32-9.
  20. Double-stranded RNA-dependent protein kinase (PKR) is a stress-responsive kinase that induces NFkappaB-mediated resistance against mercury cytotoxicity.
    Frémont M, Vaeyens F, Herst CV, De Meirleir KL, Englebienne P.
    Life Sci. 2006 Mar 13;78(16):1845-56. Epub 2005 Dec 1
  21. Employment status in chronic fatigue syndrome. A cross-sectional study examining the value of exercise testing and self-reported measures for the assessment of employment status.
    Nijs J, Van de Putte K, Louckx F, De Meirleir K.
    Clin Rehabil. 2005 Dec;19(8):895-9.
  22. Impairments of the 2-5A synthetase/RNase L pathway in chronic fatigue syndrome.
    Nijs J, De Meirleir K.
    In Vivo. 2005 Nov-Dec;19(6):1013-21. Review.
  23. Chronic fatigue syndrome: exercise performance related to immune dysfunction.
    Nijs J, Meeus M, McGregor NR, Meeusen R, de Schutter G, van Hoof E, de Meirleir K.
    Med Sci Sports Exerc. 2005 Oct;37(10):1647-54.
  24. Nitric oxide and chronic fatigue syndrome: Are we caring for our patients or are we practicing selfcare?
    Nijs J, De Meirleir K.
    Med Hypotheses. 2006;66(2):449-50. Epub 2005 Oct 10. No abstract available.
  25. 37-Kilodalton/83-kilodalton RNase L isoform ratio in peripheral blood mononuclear cells: analytical performance and relevance for chronic fatigue syndrome.
    Frémont M, Vaeyens F, Herst CV, De Meirleir K, Englebienne P.
    Clin Diagn Lab Immunol. 2005 Oct;12(10):1259-60; author reply 1260. No abstract available.
  26. The Chronic Fatigue Syndrome Activities and Participation Questionnaire (CFS-APQ): an overview.
    Nijs J, Vaes P, De Meirleir K.
    Occup Ther Int. 2005;12(2):107-21.
  27. 2′,5′-Oligoadenylate size is critical to protect RNase L against proteolytic cleavage in chronic fatigue syndrome.
    Frémont M, El Bakkouri K, Vaeyens F, Herst CV, De Meirleir K, Englebienne P.
    Exp Mol Pathol. 2005 Jun;78(3):239-46. Epub 2005 Mar 2.
  28. Oxidative stress might reduce essential fatty acids in erythrocyte membranes of chronic fatigue syndrome patients.
    Nijs J, De Meirleir K.
    Nutr Neurosci. 2004 Aug;7(4):251-3. No abstract available.
  29. Pain in patients with chronic fatigue syndrome: does nitric oxide trigger central sensitisation?
    Nijs J, Van de Velde B, De Meirleir K.
    Med Hypotheses. 2005;64(3):558-62.
  30. Prediction of peak oxygen uptake in patients fulfilling the 1994 CDC criteria for chronic fatigue syndrome.
    Nijs J, De Meirleir K.
    Clin Rehabil. 2004 Nov;18(7):785-92.
  31. Kinesiophobia in chronic fatigue syndrome: assessment and associations with disability.
    Nijs J, De Meirleir K, Duquet W.
    Arch Phys Med Rehabil. 2004 Oct;85(10):1586-92.
  32. Norandrosterone and noretiocholanolone concentration before and after submaximal standardized exercise.
    de Geus B, Delbeke F, Meeusen R, Van Eenoo P, De Meirleir K, Busschaert B.
    Int J Sports Med. 2004 Oct;25(7):528-32.
  33. Chronic fatigue syndrome: lack of association between pain-related fear of movement and exercise capacity and disability.
    Nijs J, Vanherberghen K, Duquet W, De Meirleir K.
    Phys Ther. 2004 Aug;84(8):696-705.
  34. Chronic fatigue syndrome: intracellular immune deregulations as a possible etiology for abnormal exercise response.
    Nijs J, De Meirleir K, Meeus M, McGregor NR, Englebienne P.
    Med Hypotheses. 2004;62(5):759-65.
  35. Disability evaluation in chronic fatigue syndrome: associations between exercise capacity and activity limitations/participation restrictions.
    Nijs J, De Meirleir K, Wolfs S, Duquet W.
    Clin Rehabil. 2004 Mar;18(2):139-48.
  36. Hormonal responses during prolonged exercise are influenced by a selective DA/NA reuptake inhibitor.
    Piacentini MF, Meeusen R, Buyse L, De Schutter G, De Meirleir K.
    Br J Sports Med. 2004 Apr;38(2):129-33.
    PMID: 15039245 Free PMC Article
  37. Atypical depression as a secondary symptom in chronic fatigue syndrome.
    Van Hoof E, Cluydts R, De Meirleir K.
    Med Hypotheses. 2003 Jul;61(1):52-5.
  38. Psychometric properties of the Dutch Chronic Fatigue Syndrome–Activities and Participation Questionnaire (CFS-APQ).
    Nijs J, Vaes P, McGregor N, Van Hoof E, De Meirleir K.
    Phys Ther. 2003 May;83(5):444-54.
  39. Associations between bronchial hyperresponsiveness and immune cell parameters in patients with chronic fatigue syndrome.
    Nijs J, De Becker P, De Meirleir K, Demanet C, Vincken W, Schuermans D, McGregor N.
    Chest. 2003 Apr;123(4):998-1007.
  40. Type I interferons induce proteins susceptible to act as thyroid receptor (TR) corepressors and to signal the TR for destruction by the proteasome: possible etiology for unexplained chronic fatigue.
    Englebienne P, Verhas M, Herst CV, De Meirleir K.
    Med Hypotheses. 2003 Feb;60(2):175-8
  41. Chronic fatigue syndrome: a risk factor for osteopenia?
    Nijs J, De Meirleir K, Englebienne P, McGregor N.
    Med Hypotheses. 2003 Jan;60(1):65-8.
  42. High prevalence of Mycoplasma infections among European chronic fatigue syndrome patients. Examination of four Mycoplasma species in blood of chronic fatigue syndrome patients.
    Nijs J, Nicolson GL, De Becker P, Coomans D, De Meirleir K.
    FEMS Immunol Med Microbiol. 2002 Nov 15;34(3):209-14.
  43. No effect of a noradrenergic reuptake inhibitor on performance in trained cyclists.
    Piacentini MF, Meeusen R, Buyse L, De Schutter G, Kempenaers F, Van Nijvel J, De Meirleir K.
    Med Sci Sports Exerc. 2002 Jul;34(7):1189-93.
  44. Ribonuclease L proteolysis in peripheral blood mononuclear cells of chronic fatigue syndrome patients.
    Demettre E, Bastide L, D’Haese A, De Smet K, De Meirleir K, Tiev KP, Englebienne P, Lebleu B.
    J Biol Chem. 2002 Sep 20;277(38):35746-51. Epub 2002 Jul 12.
  45. Structural and functional features of the 37-kDa 2-5A-dependent RNase L in chronic fatigue syndrome.
    Shetzline SE, Martinand-Mari C, Reichenbach NL, Buletic Z, Lebleu B, Pfleiderer W, Charubala R, De Meirleir K, De Becker P, Peterson DL, Herst CV, Englebienne P, Suhadolnik RJ.
    J Interferon Cytokine Res. 2002 Apr;22(4):443-56.
  46. Antiviral pathway activation in chronic fatigue syndrome and acute infection.
    De Meirleir K, Suhadolnik RJ, Lebleu B, Englebienne P.
    Clin Infect Dis. 2002 May 15;34(10):1420-1; author reply 1421-2. No abstract available.
  47. Brain microdialysis in exercise research.
    Meeusen R, Piacentini MF, De Meirleir K.
    Sports Med. 2001;31(14):965-83. Review.
  48. A definition-based analysis of symptoms in a large cohort of patients with chronic fatigue syndrome.
    De Becker P, McGregor N, De Meirleir K.
    J Intern Med. 2001 Sep;250(3):234-40.
  49. Effect of exercise on portal vein blood flow in man.
    Rehrer NJ, Smets A, Reynaert H, Goes E, De Meirleir K.
    Med Sci Sports Exerc. 2001 Sep;33(9):1533-7.
  50. Exercise performance is not influenced by a 5-HT reuptake inhibitor.
    Meeusen R, Piacentini MF, Van Den Eynde S, Magnus L, De Meirleir K.
    Int J Sports Med. 2001 Jul;22(5):329-36.
  51. How significant are primary sleep disorders and sleepiness in the chronic fatigue syndrome?
    Le Bon O, Fischler B, Hoffmann G, Murphy JR, De Meirleir K, Cluydts R, Pelc I.
    Sleep Res Online. 2000;3(2):43-8.
  52. Exercise capacity in chronic fatigue syndrome.
    De Becker P, Roeykens J, Reynders M, McGregor N, De Meirleir K.
    Arch Intern Med. 2000 Nov 27;160(21):3270-7. Erratum in: Arch Intern Med 2001 Sep 10;161(16):2051-2.
  53. Relationship between muscle T2* relaxation properties and metabolic state: a combined localized 31P-spectroscopy and 1H-imaging study.
    Vandenborne K, Walter G, Ploutz-Snyder L, Dudley G, Elliott MA, De Meirleir K.
    Eur J Appl Physiol. 2000 May;82(1-2):76-82.
  54. A 37 kDa 2-5A binding protein as a potential biochemical marker for chronic fatigue syndrome.
    De Meirleir K, Bisbal C, Campine I, De Becker P, Salehzada T, Demettre E, Lebleu B.
    Am J Med. 2000 Feb;108(2):99-105.
  55. Dehydroepiandrosterone (DHEA) response to i.v. ACTH in patients with chronic fatigue syndrome.
    De Becker P, De Meirleir K, Joos E, Campine I, Van Steenberge E, Smitz J, Velkeniers B.
    Horm Metab Res. 1999 Jan;31(1):18-21.
  56. The influence of cold and compression on lymph flow at the ankle.
    Meeusen R, van der Veen P, Joos E, Roeykens J, Bossuyt A, De Meirleir K.
    Clin J Sport Med. 1998 Oct;8(4):266-71.
  57. Autonomic testing in patients with chronic fatigue syndrome.
    De Becker P, Dendale P, De Meirleir K, Campine I, Vandenborne K, Hagers Y.
    Am J Med. 1998 Sep 28;105(3A):22S-26S.
  58. Validity and reliability in a Flemish population of the WHO-MONICA Optional Study of Physical Activity Questionnaire.
    Roeykens J, Rogers R, Meeusen R, Magnus L, Borms J, de Meirleir K.
    Med Sci Sports Exerc. 1998 Jul;30(7):1071-5.
  59. Blood ammonia–heart rate relationship during graded exercise is not influenced by glycogen depletion.
    Roeykens J, Magnus L, Rogers R, Meeusen R, De Meirleir K.
    Int J Sports Med. 1998 Jan;19(1):26-31.
  60. Endurance performance in humans: the effect of a dopamine precursor or a specific serotonin (5-HT2A/2C) antagonist.
    Meeusen R, Roeykens J, Magnus L, Keizer H, De Meirleir K.
    Int J Sports Med. 1997 Nov;18(8):571-7
  61. Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome.
    Suhadolnik RJ, Peterson DL, O’Brien K, Cheney PR, Herst CV, Reichenbach NL, Kon N, Horvath SE, Iacono KT, Adelson ME, De Meirleir K, De Becker P, Charubala R, Pfleiderer W.
    J Interferon Cytokine Res. 1997 Jul;17(7):377-85.
  62. Generalized anxiety disorder in chronic fatigue syndrome.
    Fischler B, Cluydts R, De Gucht Y, Kaufman L, De Meirleir K.
    Acta Psychiatr Scand. 1997 May;95(5):405-13.
  63. Physical fatigability and exercise capacity in chronic fatigue syndrome: association with disability, somatization and psychopathology.
    Fischler B, Dendale P, Michiels V, Cluydts R, Kaufman L, De Meirleir K.
    J Psychosom Res. 1997 Apr;42(4):369-78.
  64. Endurance training effects on neurotransmitter release in rat striatum: an in vivo microdialysis study.
    Meeusen R, Smolders I, Sarre S, de Meirleir K, Keizer H, Serneels M, Ebinger G, Michotte Y.
    Acta Physiol Scand. 1997 Apr;159(4):335-41.
  65. Sleep anomalies in the chronic fatigue syndrome. A comorbidity study.
    Fischler B, Le Bon O, Hoffmann G, Cluydts R, Kaufman L, De Meirleir K.
    Neuropsychobiology. 1997;35(3):115-22.
  66. Effects of tryptophan and/or acute running on extracellular 5-HT and 5-HIAA levels in the hippocampus of food-deprived rats.
    Meeusen R, Thorré K, Chaouloff F, Sarre S, De Meirleir K, Ebinger G, Michotte Y.
    Brain Res. 1996 Nov 18;740(1-2):245-52.
  67. Cognitive functioning in patients with chronic fatigue syndrome.
    Michiels V, Cluydts R, Fischler B, Hoffmann G, Le Bon O, De Meirleir K.
    J Clin Exp Neuropsychol. 1996 Oct;18(5):666-77.
  68. Comparison of 99m Tc HMPAO SPECT scan between chronic fatigue syndrome, major depression and healthy controls: an exploratory study of clinical correlates of regional cerebral blood flow.
    Fischler B, D’Haenen H, Cluydts R, Michiels V, Demets K, Bossuyt A, Kaufman L, De Meirleir K.
    Neuropsychobiology. 1996;34(4):175-83.
  69. Exercise and brain neurotransmission.
    Meeusen R, De Meirleir K.
    Sports Med. 1995 Sep;20(3):160-88. Review.
  70. Energy-rich phosphates in slow and fast human skeletal muscle.
    Vandenborne K, Walter G, Ploutz-Snyder L, Staron R, Fry A, De Meirleir K, Dudley GA, Leigh JS.
    Am J Physiol. 1995 Apr;268(4 Pt 1):C869-76.
  71. No influence of ACTH on maximal performance.
    Soetens E, De Meirleir K, Hueting JE.
    Psychopharmacology (Berl). 1995 Apr;118(3):260-6.
  72. An early effect of acute plasma volume expansion in humans on serum erythropoietin concentration.
    Szyguła Z, Smitz J, Roeykens J, De Meirleir K, Klausen T.
    Eur J Appl Physiol Occup Physiol. 1995;72(1-2):106-10.
  73. Ectopic atrial tachycardia in a young athlete.
    Dendale P, De Meirleir K, De Wolf D.
    Med Sci Sports Exerc. 1994 Aug;26(8):937-40.
  74. 31P magnetic resonance muscle spectroscopy in fibromyalgia.
    Joos E, De Meirleir K, Vandenborne K, Neirinck P.
    J Rheumatol. 1993 Nov;20(11):1985-6. No abstract available.
  75. 1H editing of 2-deuterated exogenous and natural endogenous D-glucose in biological samples.
    Biesemans M, Kayser F, Van Cauteren M, Rehrer NJ, Neirinck P, de Meirleir K, Malaisse WJ, Willem R.
    Magn Reson Med. 1993 Jul;30(1):120-3.
  76. Exercise changes in plasma tryptophan fractions and relationship with prolactin.
    Fischer HG, Hollmann W, De Meirleir K.
    Int J Sports Med. 1991 Oct;12(5):487-9.
  77. 31P-NMR spectroscopy and the metabolic properties of different muscle fibers.
    Achten E, Van Cauteren M, Willem R, Luypaert R, Malaisse WJ, Van Bosch G, Delanghe G, De Meirleir K, Osteaux M.
    J Appl Physiol (1985). 1990 Feb;68(2):644-9.
  78. Prevalence of ventricular premature beats during stress testing in patients with exercise hypertension and the association with a positive family history of established hypertension.
    Dendale P, De Meirleir K.
    Eur Heart J. 1989 Jul;10(7):666-9.
  79. A new look to the andropause: altered function of the gonadotrophs.
    Vermeulen A, Deslypere JP, De Meirleir K.
    J Steroid Biochem. 1989 Jan;32(1B):163-5.
  80. [The behavior of arterial blood pressure in dynamic and static muscle exercise with respect to atrial natriuretic peptide and neurotransmitters].
    Hollmann W, Völker K, Heck H, Rost R, De Meirleir K.
    Z Kardiol. 1989;78 Suppl 7:211-9. Review. German
  81. Stress, physical activity and hypertension.
    De Meirleir K, Buyens G, Cooman H, Block P.
    Acta Cardiol Suppl. 1988;29:29-36. Review. No abstract available.
  82. Automated micro-method for determining L-(+)-lactate in arterialized whole blood.
    Gerlo E, Gorus F, De Meirleir K.
    Clin Chem. 1987 Jan;33(1):188-9. No abstract available.
  83. Cardiovascular effects of extreme physical training.
    Hollmann W, Rost R, De Meirleir K, Liesen H, Heck H, Mader A.
    Acta Med Scand Suppl. 1986;711:193-203.
  84. Beta-endorphin and ACTH levels in peripheral blood during and after aerobic and anaerobic exercise.
    de Meirleir K, Naaktgeboren N, Van Steirteghem A, Gorus F, Olbrecht J, Block P.
    Eur J Appl Physiol Occup Physiol. 1986;55(1):5-8.
  85. Evidence for serotoninergic control of exercise-induced prolactin secretion.
    De Meirleir K, L’Hermite-Balériaux M, L’Hermite M, Rost R, Hollmann W.
    Horm Metab Res. 1985 Jul;17(7):380-1. No abstract available.
  86. Exercise-induced prolactin release is related to anaerobiosis.
    De Meirleir KL, Baeyens L, L’Hermite-Baleriaux M, L’Hermite M, Hollmann W.
    J Clin Endocrinol Metab. 1985 Jun;60(6):1250-2.
  87. Pergolide mesylate inhibits exercise-induced prolactin release in man.
    De Meirleir K, Baeyens L, L’Hermite M, L’Hermite-Balériaux M, Olbrecht J, Holmann W.
    Fertil Steril. 1985 Apr;43(4):628-31.
  88. The role of endogenous opiates in thermal regulation of the body during exercise.
    De Meirleir K, Arentz T, Hollmann W, Vanhaelst L.
    Br Med J (Clin Res Ed). 1985 Mar 9;290(6470):739-40.
  89. Bronchogenic carcinoma: a rare cause of nontraumatic pneumopericardium.
    Rongé R, Roels P, De Meirleir K, Schandevyl W, Dewilde P, Block P.
    Acta Cardiol. 1983;38(6):565-9.
  90. Myocardial sarcoidosis: a rare cause for ventricular aneurysm.
    De Meirleir K.
    Acta Cardiol. 1982;37(1):53-8. No abstract available.
  91. Bronchodilating effect on mexiletine.
    De Meirleir K, Vincken W.
    Ann Intern Med. 1980 Oct;93(4):640. No abstract available.
  92. Hypothyroidism with normal thyroid hormone levels as a consequence of autoimmune thyroiditis and peripheral resistance to thyroid hormone.
    De Meirleir K, Golstein J, Jonckheer MH, Vanhaelst L.
    Acta Clin Belg. 1980;35(2):107-9. No abstract available.

Lisa Pavitt

Accounting

Lisa Pavitt joined the NVCBR team in 2015 and is responsible for day-to-day accounting functions. Lisa spent 10 years in the import/export field doing documentation, logistics, and letters of credits.  Lisa also worked with a small IT firm and was responsible for bookkeeping, general administration, and human resources.

Lisa is a graduate of Regis College, Weston, MA, with a BA in business and economics.

Lisa is certified in various physical fitness disciplines including pilates, water aerobics, and personal training.  In her spare time, Lisa likes to sew, work in her garden, and walk her dogs.

Shanti Rawat, M.S.

Senior Research Associate

Shanti Rawat, M.S., brings her extensive experience in microbiology to the NVCBR research team. She holds a bachelor’s degree in biology along with a master’s degree in zoology from Lucknow University. Shanti went on to receive a second master’s degree in microbiology from the University of North Dakota. She worked at the University of Nevada, Reno for 23 years in the research laboratories of Dr. Ellen Baker, Dr. Jeff Seamen, Dr. W.T. Gerthoffer, and Dr. Cherie Singer. During her tenure at the university, Shanti supervised graduate and undergraduate students, using her knowledge of molecular biology techniques. She also managed the invitrogen and promega onsite freezers and refrigerators for the entire university.   Shanti’s expertise in cell culture, molecular biology, and Western blot techniques has been instrumental to NVCBR’s research projects.

EDUCATION

  • Lucknow University, Lucknow India, Degree: Bachelor of Science, Biology, 1974; Masters of Science, Zoology, 1976
  • University of North Dakota, Grand Forks, Degree: Master of Science, Microbiology, 1987

PROFESSIONAL TRAINING

  • Cell Biology
  • Microbiology
  • Molecular Biology
  • Pharmacology

PROFESSIONAL EXPERIENCE

  • July 2011 – Present Senior Research Associate, Nevada Center for Biomedical Research, Reno, NV
  • 1998 – 2011 Research Associate, Department of Pharmacology, University of Nevada, Reno, NV
  • 1996 – 1998 Lab Technician, Department of Biochemistry, University of Nevada, Reno, NV
  • 1988 – 1996 Lab Technician, Department of Biology, University of Nevada, Reno

HONORS AND AWARDS

  • Recognition Award for 20 Years of Service, June 2010 – University of Nevada, Reno 

SELECTED PUBLICATIONS

    1. Xiong D, Heyman NS, Airey J, Zhang M, Singer CA, Rawat S, Ye L, Evans R, Burkin DJ, Tian H, McCloskey DT, Valencik M, Britton FC, Duan D, Hume JR. Cardiac-specific, inducible ClC-3 gene deletion eliminates native volume-sensitive chloride channels and produces myocardial hypertrophy in adult mice. J Mol Cell Cardiol. 2010  jan;48(1):211-9. doi: 10.1016/j.yjmcc.2009.07.003. Epub 2009 Jul 15.  PMID: 19615374 [PubMed – indexed for MEDLINE]
    2. Xiong D, Wang GX, Burkin DJ, Yamboliev IA, Singer CA, Rawat S, Scowen P, Evans R, Ye L, Hatton WJ, Tian H, Keller PS, McCloskey DT, Duan D, Hume JR.  Cardiac-specific overexpression of the human short CLC-3 chloride channel isoform in mice.    Clin Exp Pharmacol Physiol. 2009 Apr;36(4):386-93. doi: 10.1111/j.1440-1681.2008.05069.x. Epub 2008 Oct 15.  PMID: 18986326 [PubMed – indexed for MEDLINE]

Svetlana Khaiboullina, M.D., Ph.D.

Senior Research Scientist

Prior to joining the NVCBR team in 2010, Svetlana Khaiboullina, MD, PhD, worked as a research assistant professor in the Department of Microbiology and Immunology at the University of Nevada, Reno for 15 years. Dr. Khaiboullina’s research was focused on investigating various aspects of hantavirus genetics, molecular epidemiology, diagnostics, and specific prophylaxis of hantavirus disease. Her research, however, was not limited to the understanding of hantavirus pathogenesis.  She was involved in collaborative studies on various potentially fatal human pathogens including dengue virus, yellow fever virus, papilloma virus, cytomegalovirus, and E coli 0157:H7. She has authored and co-authored 28 peer-reviewed publications and has received two certificates of inventions. Dr. Khaiboullina was awarded her medical degree and PhD at the Bashkortostan State Medical Institute, Russia. Her postdoctoral educational training includes molecular biology, immunology, and vaccine development. Her primary focus at NVCBR is basic research in innate immune activation and development of diagnostic assays.

EDUCATION

  • Bashkortostan State Medical Institute, Degree: MD, Internal Medicine, 1988
  • Chelyabinsk Medical Institute, Degree: PhD, Pharmacology, 1990
    Thesis: “Study o immunotropic properties of 3-cyclohexyl aminometylazolo [3,2-a] benzimidazol dihydrochloride”

SKILLS/TRAINING

  • Pharmacology
  • Immunology
  • Cell Biology
  • Vaccine Development
  • Virology/Microbiology
  • Molecular Biology

PROFESSIONAL EXPERIENCE

  • 2010 – Present Senior Research Scientist, Nevada Center for Biomedical Research, Reno, NV
  • 2001 – 2010 Research Assistant Professor, Department of Microbiology, University of Nevada, Reno, NV; Part-time Instructor at TMCC, Reno, NV; Part-time Instructor at WNC, Carson City, NV; Part-time Research Associate at GenQuest LLC, Reno, NV
  • 1997 – 2001 Postdoctoral Fellow, Department of Microbiology, University of Nevada, Reno, NV
  • 1996 – 1997 Visiting Fellow, Cell and Molecular Biology Program, University of Nevada, Reno, NV
  • 1994 – 1997 Senior Researcher, Department of Virology, Mechnikov Research Institute for Vaccines and Sera, Ufa, Bashkortostan, Russia
  • 1992 – 1994 Junior Researcher, Department of Virology, Mechnikov Research Institute for Vaccines and Sera, Ufa, Bashkortostan, Russia
  • 1988 – 1991 Junior Researcher, Department of Pharmacology #1, Bashkortostan State Medical University, Ufa, Bashkortostan, Russia

HONORS AND AWARDS

  • Excellence in Teaching Award 2008 – TMCC
  • Phi Theta Kappa Teacher of the Year Award Nominee 2008, 2010 – TMCC
  • Junior Faculty Research Grant Award 2001 – University of Nevada, Reno
  • BRIN Grant Award 2003 – University of Nevada, Reno

MEMBERSHIPS IN PROFESSIONAL ORGANIZATIONS

  • 1996 – Present American Society for Virology
  • 1992 – 1996 Russian Society of Microbiology, Parasitology and Virology
  • 1987 – 1992 All-Union Society of Pharmacology (USSR)

PATENTS AND INVENTIONS

  • Strokin, Yu. V., E. K Alekhin, V.M. Dianov, F. Khaiboullina, S.V. Sibiryak, F. S. Zarudiy, et al. 1988. 3-cyclohexylaminomethylthyazolo[3,2-a] benzimidazole dihydrochloride, displaying immunotropic, anti-aggregational, and anti-fungal activities. Certificate of Invention # 1564997, September 15, 1988.
  • Katayev, V. A., S.V. Sibiryak, F.A. Khaliullin, R.F. Sadykov, F. Khaiboullina., et al. 1992. Piperidine salt of 2-[1-(thyetanyl-3) benzimidazolyl-2-thyo] acetic acid, displaying immunotropic activity. Certificate of Invention #1820611, October 12, 1992.

SELECTED PRESENTATIONS

  • Khaiboullina S.F., S. Lewis, D. Enria, and S.St. Jeor. 2001. Cytokine Mrna expression in hantavirus infected cells. p. 111. In Abstracts of the Fifth International Conference on Hemorrhagic Fever with Renal Syndrome (HFRS), Hantavirus Pulmonary Syndrome (HPS), and Hantaviruses, Annecy, France.
  • Khaiboullina, SF, AA Rizvanov, J. Maciejewsky, and S St Jeor. 2003. Regulation of cellular gene expression in endothelial cells by Sin Nombre and Prospect Hill viruses. In Abstr. 22 Ann Meeting of ASV, Davis CA
  • Khaiboullina, SF, V. M. Deyde, AA Rizvanov, and S St Jeor. 2004. Andes virus stimulated MxA protein expression in endothelial cells. In Abstracts of the Sixth International Conference on HFRS, HPS and Hantaviruses, Seoul, Republic of Korea.

SELECTED PUBLICATIONS

  1. Genome-wide association analysis identifies genetic variations in subjects with myalgic encephalomyelitis/chronic fatigue syndrome.
    Schlauch KA, Khaiboullina SF, De Meirleir KL, Rawat S, Petereit J, Rizvanov AA, Blatt N, Mijatovic T, Kulick D, Palotás A, Lombardi VC.
    Transl Psychiatry. 2016 Feb 9;6:e730. doi: 10.1038/tp.2015.208.
  2. Hantaviral Proteins: Structure, Functions, and Role in Hantavirus Infection.
    Muyangwa M, Martynova EV, Khaiboullina SF, Morzunov SP, Rizvanov AA.
    Front Microbiol. 2015 Nov 27;6:1326. doi: 10.3389/fmicb.2015.01326. eCollection 2015. Review.
  3. Gut-Associated Plasmacytoid Dendritic Cells Display an Immature Phenotype and Upregulated Granzyme B in Subjects with HIV/AIDS.
    Boichuk SV, Khaiboullina SF, Ramazanov BR, Khasanova GR, Ivanovskaya KA, Nizamutdinov EZ, Sharafutdinov MR, Martynova EV, DeMeirleir KL, Hulstaert J, Anokhin VA, Rizvanov AA, Lombardi VC.
    Front Immunol. 2015 Sep 24;6:485. doi: 10.3389/fimmu.2015.00485. eCollection 2015.
  4. Multiplex Analysis of Serum Cytokines in Humans with Hantavirus Pulmonary Syndrome.
    Morzunov SP, Khaiboullina SF, St Jeor S, Rizvanov AA, Lombardi VC.
    Front Immunol. 2015 Aug 31;6:432. doi: 10.3389/fimmu.2015.00432. eCollection 2015.
  5. CCL27: Novel Cytokine with Potential Role in Pathogenesis of Multiple Sclerosis.
    Khaiboullina SF, Gumerova AR, Khafizova IF, Martynova EV, Lombardi VC, Bellusci S, Rizvanov AA.
    Biomed Res Int. 2015;2015:189638. doi: 10.1155/2015/189638. Epub 2015 Jul 29.
  6. Epidemiological dynamics of nephropathia epidemica in the Republic of Tatarstan, Russia, during the period of 1997-2013.
    Khismatullina NA, Karimov MM, Khaertynov KS, Shuralev EA, Morzunov SP, Khaertynova IM, Ivanov AA, Milova IV, Khakimzyanova MB, Sayfullina GSh, Gaynullin AA, Ivanov AV, Rizvanov AA, Khaiboullina SF.
    Epidemiol Infect. 2016 Feb;144(3):618-26. doi: 10.1017/S0950268815001454. Epub 2015 Jul 10.
  7. Erythrocyte: A systems model of the control of aggregation and deformability.
    Bazanovas AN, Evstifeev AI, Khaiboullina SF, Sadreev II, Skorinkin AI, Kotov NV.
    Biosystems. 2015 May;131:1-8. doi: 10.1016/j.biosystems.2015.03.003. Epub 2015 Mar 21.
  8. Differential immuno-reactivity to genomic DNA, RNA and mitochondrial DNA is associated with auto-immunity.
    Ivanova VV, Khaiboullina SF, Cherenkova EE, Martynova EV, Nevzorova TA, Kunst MA, Sibgatullin TB, Maksudova AN, Oliveira PJ, Lombardi VC, Palotás A, Rizvanov AA.
    Cell Physiol Biochem. 2014;34(6):2200-8. doi: 10.1159/000369663. Epub 2014 Dec 4.
  9. Plasmacytoid dendritic cells, a role in neoplastic prevention and progression.
    Lombardi VC, Khaiboullina SF, Rizvanov AA.
    Eur J Clin Invest. 2015 Jan;45 Suppl 1:1-8. doi: 10.1111/eci.12363. Review.
  10. Cytokine expression provides clues to the pathophysiology of Gulf War illness and myalgic encephalomyelitis.
    Khaiboullina SF, DeMeirleir KL, Rawat S, Berk GS, Gaynor-Berk RS, Mijatovic T, Blatt N, Rizvanov AA, Young SG, Lombardi VC.
    Cytokine. 2015 Mar;72(1):1-8. doi: 10.1016/j.cyto.2014.11.019. Epub 2014 Dec 13.
  11. Inflammatory cytokines kinetics define the severity and phase of nephropathia epidemica.
    Baigildina AA, Khaiboullina SF, Martynova EV, Anokhin VA, Lombardi VC, Rizvanov AA.
    Biomark Med. 2015;9(2):99-107. doi: 10.2217/bmm.14.88. Epub 2014 Oct 14.
  12. Upregulation of IFN-γ and IL-12 is associated with a milder form of hantavirus hemorrhagic fever with renal syndrome.
    Khaiboullina SF, Martynova EV, Khamidullina ZL, Lapteva EV, Nikolaeva IV, Anokhin VV, Lombardi VC, Rizvanov AA.
    Eur J Clin Microbiol Infect Dis. 2014 Dec;33(12):2149-56. doi: 10.1007/s10096-014-2176-x. Epub 2014 Jun 19.
  13. Plasmacytoid dendritic cells of the gut: relevance to immunity and pathology.
    Lombardi VC, Khaiboullina SF.
    Clin Immunol. 2014 Jul;153(1):165-77. doi: 10.1016/j.clim.2014.04.007. Epub 2014 Apr 24. Review.
  14. Human dendritic cells transfected with a human papilloma virus-18 construct display decreased mobility and upregulated cytokine production.
    Khaiboullina SF, Morzunov SP, Hall MR, De Meirleir KL, Rizvanov AA, Lombardi VC.
    Int J Oncol. 2013 Nov;43(5):1701-9. doi: 10.3892/ijo.2013.2074. Epub 2013 Aug 21.
  15. Biological insight, high-throughput datasets and the nature of neuro-degenerative disorders.
    Valente AX, Oliveira PJ, Khaiboullina SF, Palotás A, Rizvanov AA.
    Curr Drug Metab. 2013 Sep;14(7):814-8.
  16. Death-domain associated protein-6 (DAXX) mediated apoptosis in hantavirus infection is counter-balanced by activation of interferon-stimulated nuclear transcription factors.
    Khaiboullina SF, Morzunov SP, Boichuk SV, Palotás A, St Jeor S, Lombardi VC, Rizvanov AA.
    Virology. 2013 Sep 1;443(2):338-48. doi: 10.1016/j.virol.2013.05.024. Epub 2013 Jul 3.
  17. Plasmacytoid dendritic cells in the duodenum of individuals diagnosed with myalgic encephalomyelitis are uniquely immunoreactive to antibodies to human endogenous retroviral proteins.
    De Meirleir KL, Khaiboullina SF, Frémont M, Hulstaert J, Rizvanov AA, Palotás A, Lombardi VC.
    In Vivo. 2013 Mar-Apr;27(2):177-87.
  18. Andes-virus-induced cytokine storm is partially suppressed by ribavirin.
    Khaiboullina SF, Rizvanov AA, Lombardi VC, Morzunov SP, Reis HJ, Palotás A, St Jeor S.
    Antivir Ther. 2013;18(4):575-84. doi: 10.3851/IMP2524. Epub 2013 Jan 8.
  19. Hantaviruses: molecular biology, evolution and pathogenesis.
    Khaiboullina SF, Morzunov SP, St Jeor SC.
    Curr Mol Med. 2005 Dec;5(8):773-90. Review.
  20. Yellow fever virus strains Asibi and 17D-204 infect human umbilical cord endothelial cells and induce novel changes in gene expression.
    Khaiboullina SF, Rizvanov AA, Holbrook MR, St Jeor S.
    Virology. 2005 Nov 25;342(2):167-76. Epub 2005 Sep 15.
  21. Replication and immunoactivity of the recombinant Peromyscus maniculatus cytomegalovirus expressing hantavirus G1 glycoprotein in vivo and in vitro.
    Rizvanov AA, Khaiboullina SF, van Geelen AG, St Jeor SC.
    Vaccine. 2006 Jan 16;24(3):327-34. Epub 2005 Aug 11.
  22. Andes virus stimulates interferon-inducible MxA protein expression in endothelial cells.
    Khaiboullina SF, Rizvanov AA, Deyde VM, St Jeor SC.
    J Med Virol. 2005 Feb;75(2):267-75.
  23. Development of reassortant viruses between pathogenic hantavirus strains.
    Rizvanov AA, Khaiboullina SF, St Jeor S.
    Virology. 2004 Oct 1;327(2):225-32.
  24. Regulation of cellular gene expression in endothelial cells by sin nombre and prospect hill viruses.
    Khaiboullina SF, Rizvanov AA, Otteson E, Miyazato A, Maciejewski J, St Jeor S.
    Viral Immunol. 2004;17(2):234-51.
  25. Human cytomegalovirus persists in myeloid progenitors and is passed to the myeloid progeny in a latent form.
    Khaiboullina SF, Maciejewski JP, Crapnell K, Spallone PA, Dean Stock A, Pari GS, Zanjani ED, Jeor SS.
    Br J Haematol. 2004 Aug;126(3):410-7.
  26. Tumor development and cytokine production by human colon tissues and carcinoma cell lines.
    Mohammadpour H, Hall MR, Pardini RS, Pardini L, Khaiboullina SF, Manalo P, McGregor B.
    Int J Surg Investig. 2000;2(1):65-72.
  27. Lymphocyte Apoptosis during Hemorragic Fever with Renal Syndrome.
    Akhmatova NK, Yusupova RS, Khaiboullina SF, Sibiryak SV.
    Russ J Immunol. 2003 Apr;8(1):37-46.
  28. Hantavirus immunology.
    Khaiboullina SF, St Jeor SC.
    Viral Immunol. 2002;15(4):609-25. Review.
  29. Shiga toxin-producing Escherichia coli in beef heifers grazing an irrigated pasture.
    Thran BH, Hussein HS, Hall MR, Khaiboullina SF.
    J Food Prot. 2001 Oct;64(10):1613-6.
  30. Occurrence of verotoxin-producing Escherichia coli in dairy heifers grazing an irrigated pasture.
    Thran BH, Hussein HS, Hall MR, Khaiboullina SF.
    Toxicology. 2001 Feb 28;159(3):159-69.
  31. Effects of tumor necrosis factor alpha on sin nombre virus infection in vitro.
    Khaiboullina SF, Netski DM, Krumpe P, St Jeor SC.
    J Virol. 2000 Dec;74(24):11966-71.
  32. An atraumatic method to establish human colon carcinoma in long-term culture.
    Mohammadpour H, Hall MR, Pardini RS, Khaiboullina SF, Manalo P, McGregor B.

Vincent C. Lombardi, Ph.D.

Research Director

Vincent C. Lombardi, PhD, began his work in ME/CFS in 1992, characterizing T-cell populations in ME/CFS patients, in collaboration with Dr. Daniel Peterson. He later continued his ME/CFS research in the laboratory of Dr. Robert Suhadolnik at Temple University, studying the interferon-regulated RNase L antiviral pathway and its involvement in ME/CFS. Dr. Lombardi completed his graduate degree at the University of Nevada, Reno, receiving his PhD in biochemistry in 2005. The primary focus of his PhD thesis was the isolation and characterization of novel diuretic neuropeptides. In addition to his academic research, Dr. Lombardi has also developed specialty clinical diagnostic tools in collaboration with eminent ME/CFS physicians such as Dr. Kenny De Meirleir. These diagnostic tests have helped ME/CFS physicians identify and treat areas of deficiency.

Upon joining NVCBR in July 2007, Dr. Lombardi’s research efforts focused on the inflammatory component of ME/CFS with a special emphasis on the interferon response.

As the leader of NVCBR’s research team, Dr. Lombardi continues to focus his research efforts in neuro-immune diseases and the innate immune system, including potential pathogens, with a focus on the innate immune response in the interferon system.

EDUCATION

  • Bachelor of Arts in Science with an emphasis in Biology, Sierra Nevada College, Incline Village, Nevada, May 1995 magna cum laude
  • Temple University, Philadelphia, PA, PhD candidate July 1998 – December 1998
  • University of Nevada, Reno, NV, PhD Biochemistry Spring 2000 – 2006

SKILLS/ TRAINING

  • Mathematical Modeling
  • Molecular Modeling
  • Biostatistics
  • Analytical Chemistry
  • Organic Spectroscopy
  • Protein Purification: Assay Development, HPLC method development 
  • Virology/Microbiology
  • Biochemistry
  • Clinical Diagnostics
  • Project Management
  • Molecular Biology
  • MSDS and Safety Officer
  • Protein Chemistry

PROFESSIONAL EXPERIENCE

  • 2011 – present Director of Research, Nevada Center for Biomedical Research, Reno, NV
  • 2011 – 2015 Director of Operations, Unevx Clinical Laboratory, Reno, NV
  • 2010 – 2011 Director of Basic Research, Whittemore Peterson Institute for Neuro-Immune Disease, Reno, NV, Research Focus: Interferon Response in ME/CFS
  • 2006 – present Assistant Clinical Professor of Microbiology & Immunology, Assistant Clinical Professor of Pathology, University of Nevada, Reno, NV
  • 2007 – 2010 Postdoctoral Fellow, Whittemore Peterson Institute for Neuro-Immune Disease, Reno, NV, Research focus: Cytokine and Chemokine Response in ME/CFS
  • 2004 – 2009 Director of Operations, Lead Scientist for Product Development, Redlabs, USA, Reno, NV
  • 2001 – 2005 Graduate Student, Doctoral Candidate, University of Nevada, Reno NV (David Schooley, PI)
  • 1999 – 2000 Graduate Student, Doctoral Candidate, Temple University Philidelphia, PA (Robert Suhadolnik, PI)
  • 1992 – 1999 President, Casa Bella Holdings, Inc., Investment Banker, Crystal Bay NV
  • 1983 – 1992 Executive Vice President, Securities Trader, Securities Broker, General Principle, Options and Futures Principle, Commodities Principle, Managed 37 Securities Brokers (Series 3, 4, 7, 24 and 63 Securities Licenses)
  • JP Michael Securities, Burbank, CA, Osborne Securities, Los Angeles, CA, Toluca Pacific Securities, Crystal Bay, NV

HONORS AND AWARDS

  • Eli Lilly Poster Award – Protein Society Meeting
  • Salutatorian, Sierra Nevada College 1995
  • Outstanding Science Student of Graduating Class 1995
  • General Motors Liberal Arts Excellent Awards Program 1993
  • CRC Academic Award 1994

MEMBERSHIPS IN PROFESSIONAL ORGANIZATIONS

  • 2008 – Present: International Society for Interferon and Cytokine Research

PATENTS AND INVENTIONS

  • Lombardi, Vincent C, Schooley, David A: Method for selective conjugation of analytes to enzymes without unwanted enzyme-enzyme cross-linking. University And Community College System Of May, 30 2003: WO 2003/043978

SELECTED PRESENTATIONS

  • CD-4/CD-8 Rations in Chronic Fatigue and AIDS Patients, American Mathematical Society Conference (Invited Speaker), University of Oregon, 1993
  • Cytokine and Chemokine Signatures in CFS Patients, AAFCF Annual Conference (Invited Speaker), Reno, NV, 2007

SELECTED PUBLICATIONS

  1. Decreased Numbers of CD57+CD3- Cells Identify Potential Innate Immune Differences in Patients with Autism Spectrum Disorder.
    Siniscalco D, Mijatovic T, Bosmans E, Cirillo A, Kruzliak P, Lombardi VC, DE Meirleir K, Antonucci N.
    In Vivo. 2016 03-04;30(2):83-89.
  2. Genome-wide association analysis identifies genetic variations in subjects with myalgic encephalomyelitis/chronic fatigue syndrome.
    Schlauch KA, Khaiboullina SF, De Meirleir KL, Rawat S, Petereit J, Rizvanov AA, Blatt N, Mijatovic T, Kulick D, Palotás A, Lombardi VC.
    Transl Psychiatry. 2016 Feb 9;6:e730. doi: 10.1038/tp.2015.208.
  3. Gut-Associated Plasmacytoid Dendritic Cells Display an Immature Phenotype and Upregulated Granzyme B in Subjects with HIV/AIDS.
    Boichuk SV, Khaiboullina SF, Ramazanov BR, Khasanova GR, Ivanovskaya KA, Nizamutdinov EZ, Sharafutdinov MR, Martynova EV, DeMeirleir KL, Hulstaert J, Anokhin VA, Rizvanov AA, Lombardi VC.
    Front Immunol. 2015 Sep 24;6:485. doi: 10.3389/fimmu.2015.00485. eCollection 2015.
  4. Multiplex Analysis of Serum Cytokines in Humans with Hantavirus Pulmonary Syndrome.
    Morzunov SP, Khaiboullina SF, St Jeor S, Rizvanov AA, Lombardi VC.
    Front Immunol. 2015 Aug 31;6:432. doi: 10.3389/fimmu.2015.00432. eCollection 2015.
  5. CCL27: Novel Cytokine with Potential Role in Pathogenesis of Multiple Sclerosis.
    Khaiboullina SF, Gumerova AR, Khafizova IF, Martynova EV, Lombardi VC, Bellusci S, Rizvanov AA.
    Biomed Res Int. 2015;2015:189638. doi: 10.1155/2015/189638. Epub 2015 Jul 29.
  6. Differential immuno-reactivity to genomic DNA, RNA and mitochondrial DNA is associated with auto-immunity.
    Ivanova VV, Khaiboullina SF, Cherenkova EE, Martynova EV, Nevzorova TA, Kunst MA, Sibgatullin TB, Maksudova AN, Oliveira PJ, Lombardi VC, Palotás A, Rizvanov AA.
    Cell Physiol Biochem. 2014;34(6):2200-8. doi: 10.1159/000369663. Epub 2014 Dec 4.
  7. Plasmacytoid dendritic cells, a role in neoplastic prevention and progression.
    Lombardi VC, Khaiboullina SF, Rizvanov AA.
    Eur J Clin Invest. 2015 Jan;45 Suppl 1:1-8. doi: 10.1111/eci.12363. Review.
  8. Cytokine expression provides clues to the pathophysiology of Gulf War illness and myalgic encephalomyelitis.
    Khaiboullina SF, DeMeirleir KL, Rawat S, Berk GS, Gaynor-Berk RS, Mijatovic T, Blatt N, Rizvanov AA, Young SG, Lombardi VC.
    Cytokine. 2015 Mar;72(1):1-8. doi: 10.1016/j.cyto.2014.11.019. Epub 2014 Dec 13.
  9. Inflammatory cytokines kinetics define the severity and phase of nephropathia epidemica.
    Baigildina AA, Khaiboullina SF, Martynova EV, Anokhin VA, Lombardi VC, Rizvanov AA.
    Biomark Med. 2015;9(2):99-107. doi: 10.2217/bmm.14.88. Epub 2014 Oct 14.
  10. Upregulation of IFN-γ and IL-12 is associated with a milder form of hantavirus hemorrhagic fever with renal syndrome.
    Khaiboullina SF, Martynova EV, Khamidullina ZL, Lapteva EV, Nikolaeva IV, Anokhin VV, Lombardi VC, Rizvanov AA.
    Eur J Clin Microbiol Infect Dis. 2014 Dec;33(12):2149-56. doi: 10.1007/s10096-014-2176-x. Epub 2014 Jun 19.
  11. Plasmacytoid dendritic cells of the gut: relevance to immunity and pathology.
    Lombardi VC, Khaiboullina SF.
    Clin Immunol. 2014 Jul;153(1):165-77. doi: 10.1016/j.clim.2014.04.007. Epub 2014 Apr 24. Review.
  12. Human dendritic cells transfected with a human papilloma virus-18 construct display decreased mobility and upregulated cytokine production.
    Khaiboullina SF, Morzunov SP, Hall MR, De Meirleir KL, Rizvanov AA, Lombardi VC.
    Int J Oncol. 2013 Nov;43(5):1701-9. doi: 10.3892/ijo.2013.2074. Epub 2013 Aug 21.
  13. Death-domain associated protein-6 (DAXX) mediated apoptosis in hantavirus infection is counter-balanced by activation of interferon-stimulated nuclear transcription factors.
    Khaiboullina SF, Morzunov SP, Boichuk SV, Palotás A, St Jeor S, Lombardi VC, Rizvanov AA.
  14. Plasmacytoid dendritic cells in the duodenum of individuals diagnosed with myalgic encephalomyelitis are uniquely immunoreactive to antibodies to human endogenous retroviral proteins.
    De Meirleir KL, Khaiboullina SF, Frémont M, Hulstaert J, Rizvanov AA, Palotás A, Lombardi VC.
    In Vivo. 2013 Mar-Apr;27(2):177-87.
  15. Andes-virus-induced cytokine storm is partially suppressed by ribavirin.
    Khaiboullina SF, Rizvanov AA, Lombardi VC, Morzunov SP, Reis HJ, Palotás A, St Jeor S.
    Antivir Ther. 2013;18(4):575-84. doi: 10.3851/IMP2524. Epub 2013 Jan 8.
  16. Presence and activity of a Dippu-DH31-like peptide in the blood-feeding bug, Rhodnius prolixus.
    Te Brugge VA, Lombardi VC, Schooley DA, Orchard I.
    Peptides. 2005 Jan;26(1):29-42. Erratum in: Peptides. 2005 Jul;26(7):1283.
  17. A method for selective conjugation of an analyte to enzymes without unwanted enzyme-enzyme cross-linking.
    Lombardi VC, Schooley DA.
    Anal Biochem. 2004 Aug 1;331(1):40-5.